Clinical trial · Interventional
Dose-reduced Versus Standard Conditioning in MDS/sAML
Dose-reduced Versus Standard Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients With MDS or sAML: A Randomised Phase III Study (RICMAC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this trial dose reduced conditioning is compared to standard conditioning followed by allogeneic stem cell transplantation from related or unrelated donors in patients with MDS or secondary AML. Conditioning is the very high dose chemotherapy treatment that is given in the days before the stem cell transplant. The hypothesis is that a dose reduced conditioning will reduce the non-relapse mortality from 40% to 20% at one year after allogeneic stem cell transplantation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
| Secondary Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Myeloablative conditioning | Other | — | UNRESOLVED |
| Reduced Intensity Conditioning | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- A
- description
- Myeloablative conditioning
- interventionNames
- Other: Myeloablative conditioning
- type
- EXPERIMENTAL
- label
- B
- description
- Reduced Intensity Conditioning
- interventionNames
- Other: Reduced Intensity Conditioning
Primary outcomes (1)
- measure
- non-relapse mortality
- timeFrame
- every 6 months for safety and in the final analysis at one year after allogeneic stem cell transplantation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Disease: Cytologically proven primary or therapy-related myelodysplastic syndrome (MDS), either as * refractory anaemia (RA) according FAB or RA with or without dysplasia according WHO, * refractory anaemia with ringsideroblasts (RARS) according FAB or RARS with or without dysplasia according WHO, * refractory anaemia with excess of blasts (RAEB) according FAB or RAEB I or RAEB II according WHO, * refractory anaemia with excess of blast in transformation (RAEB T) according FAB, * CMML (dysplastic type) according WHO, * or secondary acute myeloid leukaemia (sAML). * Blast count \< 20 percent in bone marrow with or without chemotherapy at time of transplantation. * Patient eligible for standard and dose-reduced conditioning as per local guideline. * Patient age 18 - 60 years if donor is a HLA-matched unrelated donor (HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1) (one mismatch allowed): * Patient age 18 - 65 years if donor is a HLA-matched related donor ((HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1) (one anti¬gen-mismatch allowed): * No major organ dysfunction. * Written informed consent of the patient. Exclusion Criteria: * Blasts \> 20 % in bone marrow at time of transplantation * No written informed consent. * Central nervous involvement. * Severe irreversible renal, hepatic, pulmonary or cardiac disease, such as * Total bilirubin, SGPT or SGOT \> 2 times upper the normal level. * Left ventricular ejection fraction \< 30 %. * Creatinine clearance \< 30 ml/min. * DLCO \< 35 % and/or receiving supplementary continuous oxygen. * Positive serology for HIV. * Pregnant or lactating women. * Patients with a life-expectancy of less than six months because of another debilitating disease. * Serious psychiatric or psychological disorders. * Invasive fungal infection at time of registration.
References
Publications (0)
Data not yet available